Ramucirumab: A Promising Strategy for EGFR Mutant NSCLC

Dear Dr. Renukaprasad A R, How does ramucirumab improve clinical outcomes in patients with epidermal growth factor receptor mutation-positive (EGFR M+) metastatic non-small cell lung cancer (NSCLC)? Ramucirumab and erlotinib combination therapy has shown comparable efficacy to the best-in-class treatment options for previously untreated patients with EGFR M+ metastatic NSCLC. Join us TODAY at 07:30 PM IST to get experts' insights on the role of ramucirumab in NSCLC management! Stay tuned for this informative discussion! Highlights: Lung cancer evolution over the last three decades - Dr. P. S. Dattatreya Options for choosing first-line treatment of EGFR M+ metastatic NSCLC - Prof. Ernest Nadal Ramuricumab as second-line treatment of EGFR M+ metastatic NSCLC - Prof. Ernest Nadal Panel Discussion: Management of metastatic NSCLC evidence from clinics - Moderator: Dr. P. S. Dattatreya Join the Session Docplexus: One of the world's largest online communities of Doctors Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*